“We are overjoyed to have seen such strong support from shareholders, particularly amidst challenging market conditions,” Wellnex CEO George Karafotias said.
“The total $5.965 million in funds raised will enable us to progress on our goal to be one of the first companies to offer an over-the-counter medicinal cannabis product in the Australian market.”
“We are keenly focused on continuing to generate value for shareholders, with a strong pipeline of brand and product launches in the remainder of FY23 that will further accelerate revenue and margins,” Mr Karafotias said.
31st May 2024
8th May 2024
4th May 2024
Any advice provided by Reach Markets including on its website and by its representatives is general advice only and does not consider your objectives, financial situation or needs, and you should consider whether it is appropriate for you. This might mean that you need to seek personal advice from a representative authorised to provide personal advice. If you are thinking about acquiring a financial product, you should consider our Financial Services Guide (FSG)
including the Privacy Statement and any relevant Product Disclosure Statement or Prospectus (if one is available) to understand the features, risks and returns associated with the investment.
Please click here to read our full warning.